Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IVF vs ILLR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
IVF Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 4–4 Matrix Metrics)
IVF Overall Winner
6-Pillar Tally: IVF 4 – 0 ILLR (2 Tie)
Matrix Metrics: IVF 4 – 4 ILLR
As of Nov 16, 2026, INVO Fertility, Inc. (IVF) is the stronger overall head-to-head candidate over Triller Group Inc. (ILLR) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IVF carries a Unified Composite Score of 29.8/100 (SELL) at $2.38 (N/M Forward P/E, -78.7% operating margin), whereas ILLR carries 48.6/100 (HOLD) at $0.18 (N/M Forward P/E, -432.7% operating margin).
- Composite vs. Pillar Nuance: While ILLR currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. IVF 29.8/100 SELL), IVF captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-78.7% vs. -432.7% operating margin) and revenue trajectory (+16.7% vs. -5.2% YoY).
- Technical & Structure Timing Caution: IVF trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.0); meanwhile ILLR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About IVF vs ILLR
IVF
Head-to-Head Winner
INVO Fertility, Inc. Common Stock
$2.38
-8.46% 1D
Market Cap
$3.2M
TTM Revenue
$7.5M
Forward P/E
N/M
Beta / 30D Vol
-7.15β · 888% Vol
Unified Composite Score
29.8
SELL
Tech 50.0
Fund 26.0
Flow 50.0
Mom 34.0
Weinstein Technical Phase
Markup · Hold / add on dips
ILLR
Triller Group Inc. Common Stock
$0.18
-23.04% 1D
Market Cap
$4.7M
TTM Revenue
$22M
Forward P/E
N/M
Beta / 30D Vol
-10.16β · 177% Vol
Unified Composite Score
48.6
HOLD
Tech 45.0
Fund 49.0
Flow 50.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (IVF 4 – 0 ILLR)
1. Valuation Multiples
IVF
Forward P/E
N/M
N/M
Trailing P/E
0.0x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.3x
0.2x
2. Growth & Scale
IVF
Revenue Growth (YoY)
+16.7%
-5.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$7.5M
$22M
Market Cap
$3.2M
$4.7M
3. Profitability & Quality
IVF
Gross Margin
35.3%
N/A
Operating Margin
-78.7%
-432.7%
Net Profit Margin
-92.3%
0.0%
Return on Equity (ROE)
-72.7%
0.0%
4. Balance Sheet & Cash Flow
IVF
Cash Generation (TTM)
-$5.4M
-$144M EBITDA
Cash Flow Margin
-71.9%
N/A
Net Cash / Leverage
-$919,426 Net Debt (0.27x D/E)
0.0% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Software - Application Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: IVF (4) vs ILLR (4)| Institutional Metric | IVF | ILLR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $3.2M | $4.7M | Tie | |
| Trailing P/E Ratio | 0.0x | N/M | IVF | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +16.7% | -5.2% | IVF | |
| Operating Margin (TTM) | -78.7% | -432.7% | IVF | |
| Net Profit Margin | -92.3% | 0.0% | ILLR | |
| Return on Equity (ROE) | -72.7% | 0.0% | ILLR | |
| 52-Week Range Position | 49% ($0–$5) | 1% ($0–$5) | IVF | |
| Beta / 30D Volatility | -7.15β · 888% Vol | -10.16β · 177% Vol | ILLR | |
| Unified Institutional Score | 29.8 / 100 (SELL) | 48.6 / 100 (HOLD) | ILLR | |
| Trailing 12M Revenue (USD) | $7.5M | $22M | Scale | |
| Gross Profit Margin (TTM) | 35.3% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.3x EV/Rev | N/M PEG · 0.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$5.4M (-$919,426 Net Debt (0.27x D/E)) | -$144M EBITDA (0.0% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
IVF +61.21 pp
3M Horizon
IVF +54.78 pp
6M Horizon
IVF +47.45 pp
1Y Horizon
IVF +125.04 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IVF Revenue | ILLR Revenue | IVF Op. Margin | ILLR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -532.8% | N/A | IVF |
| FY2019 | $0M | N/A | -120.8% | N/A | IVF |
| FY2020 | $0M | N/A | -531.7% | N/A | IVF |
| FY2021 | $0M | $10M | -125.4% | -73.7% | ILLR |
| FY2022 | $0M | $30M | -1292.5% | -91.2% | ILLR |
| FY2023 | $0M | $50M | -224.0% | -79.5% | ILLR |
| FY2024 | $10M | $30M | -101.0% | -411.9% | IVF |
| FY2025 | $10M | $20M | -105.8% | -640.1% | IVF |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
IVF
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact IVF Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ILLR
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ILLR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
IVF Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ILLR Moat Profile
Cyclical / Execution-Driven Positioning
Software - Application Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ IVF vs ILLR Key Questions & Quantitative Answers
As of Nov 16, 2026, INVO Fertility, Inc. (IVF) is the stronger overall head-to-head candidate over Triller Group Inc. (ILLR) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IVF carries a Unified Composite Score of 29.8/100 (SELL) at $2.38 (N/M Forward P/E, -78.7% operating margin), whereas ILLR carries 48.6/100 (HOLD) at $0.18 (N/M Forward P/E, -432.7% operating margin). Composite vs. Pillar Nuance: While ILLR currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. IVF 29.8/100 SELL), IVF captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-78.7% vs. -432.7% operating margin) and revenue trajectory (+16.7% vs. -5.2% YoY). Technical & Structure Timing Caution: IVF trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.0); meanwhile ILLR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IVF leads the Growth & Scale pillar: IVF posts +16.7% YoY revenue growth and +0.0% YoY earnings growth on $7.5M TTM revenue (35.3% gross margin, -78.7% operating margin), compared with ILLR at -5.2% YoY revenue growth and +0.0% YoY earnings growth on $22M TTM revenue (N/A gross margin, -432.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IVF cumulative revenue shifted +0.0% while ILLR shifted +100.0%. In operating R&D and SG&A reinvestment, IVF deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ILLR.
IVF screens cheaper on headline valuation multiples. IVF trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-71.9% FCF margin), whereas ILLR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.2x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IVF (-72.7% ROE) versus ILLR (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, IVF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.15β · 888% Vol realized risk). By comparison, ILLR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-10.16β · 177% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ILLR vs IVF · Reverse Pair
ILLR vs SDOT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal